Neurogene Inc. (NGNE)
NASDAQ: NGNE
· Real-Time Price · USD
14.73
-0.27 (-1.80%)
At close: May 09, 2025, 3:59 PM
14.73
0.00%
After-hours: May 09, 2025, 04:05 PM EDT
-1.80% (1D)
| Bid | 14.66 |
| Market Cap | 210.08M |
| Revenue (ttm) | 925K |
| Net Income (ttm) | -75.14M |
| EPS (ttm) | -4.28 |
| PE Ratio (ttm) | -3.44 |
| Forward PE | -2.84 |
| Analyst | Buy |
| Ask | 17.94 |
| Volume | 155,724 |
| Avg. Volume (20D) | 262,300 |
| Open | 14.65 |
| Previous Close | 15.00 |
| Day's Range | 13.70 - 16.00 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.56 |
About NGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-42.58%
Neurgogene shares are trading lower after the comp...
Unlock content with
Pro Subscription
6 months ago
-44.08%
Neurogene shares are trading lower. The company issued interim efficacy data from its first four low-dose pediatric participants in NGN-401 gene therapy clinical trial for Rett Syndrome.
